Rationale: The prevalence of HIV-associated pulmonary arterial hypertension (PAH) has
not been evaluated since introduction of combined, highly active antiretroviral treatments. …

Background & Aims HDV infection causes severe chronic liver disease in individuals infected
with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, …

Background Therapeutic control of HIV replication reduces the size of the viral reservoir,
particularly among central memory CD4+ T cells, and this effect might be accentuated by early …

Background & Aims In the presence of highly-potent antivirals, persistence of hepatitis B
virus (HBV) is most well-characterized by covalently-closed circular DNA (cccDNA) and total …

Objective: To describe and explain the syndrome of HIV-associated cryptogenic liver disease
in eight consecutive patients suffering from portal hypertension. Methods: The study was …

Background: Little is know about the determinants of liver fibrosis progression and genomic
variability in hepatitis B virus (HBV) in HIV/HBV-coinfected patients. Methods: A cross-…

Background In France, it is estimated that 24% of HIV-infected patients are also infected with
HCV. Longitudinal studies addressing clinical and public health questions related to HIV-…

Optimizing therapeutic strategies for an HIV cure requires better understanding the characteristics
of early HIV-1 spread among resting CD4+ cells within the first month of primary HIV-1 …

Background. Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)–coinfected patients
with cirrhosis have long been considered to be difficult to treat, and real-life efficacy and …

BACKGROUND/AIMS: The aim of this study was to compare the performance of 11 biochemical
scores to estimate liver fibrosis in HIV/HBV co-infection. METHODS: Performance was …